ClinicalTrials.gg

Program

daridorexant

Also written as “Daridorexant”, “ACT-541468” and “Daridorexant 25 mg”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Sleep Apnea, Obstructive · Renal Insufficiency · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Furthest: phase 4, since Oct 25, 202234 company-led studies, 1 open or runningNext primary completion: Nov 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Idorsia Pharmaceuticals311 open or runningphase 4since Oct 25, 2022Aug 14, 2015Nov 22, 2027phase 3 · NCT07843329
Simcere Pharmaceutical Group20 open or runningphase 3since Aug 20, 2023Aug 20, 2023none ahead
Nxera Pharma Korea10 open or runningphase 3since Jun 11, 2025Jun 11, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Aug 14, 2015.

  1. Mar 21, 20192 phase 1 studies in HealthyIdorsia Pharmaceuticals · NCT03907215, NCT03892902
  2. Jul 16, 2019Phase 1 study in Renal InsufficiencyIdorsia Pharmaceuticals · NCT04024332 · 16 enrolled · Germany
  3. Jan 30, 2020Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT04250506 · 36 enrolled · Czechia
  4. May 12, 2020Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT04390334 · 24 enrolled · Germany
  5. Jun 14, 2022Phase 2 study in Sleep Initiation and Maintenance DisordersIdorsia Pharmaceuticals · NCT05423717 · 166 enrolled · United States, Bulgaria, Germany and more
  6. Jul 11, 20223 phase 1 studiesIdorsia Pharmaceuticals · NCT05458193, NCT05480488, NCT05480475
  7. Oct 25, 2022Phase 4 study in Sleep Initiation and Maintenance DisordersIdorsia Pharmaceuticals · NCT05597020 · 60 enrolled · United States, Germany, Spain
  8. Nov 8, 2022Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT05632393 · 10 enrolled · United States
  9. Jan 5, 2023Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT05702177 · 36 enrolled · Netherlands
  10. May 17, 2023Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT05877222 · 38 enrolled · United States
  11. Aug 20, 2023Simcere Pharmaceutical Group's first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT06010693 · 206 enrolled · China
  12. Feb 17, 2024Phase 1 study in Healthy VolunteerSimcere Pharmaceutical Group · NCT06326723 · 32 enrolled · China
  13. Jun 11, 2025Nxera Pharma Korea's first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Nxera Pharma KoreaNxera Pharma Korea · NCT07028697 · 164 enrolled · South Korea
  14. Sep 21, 2026Phase 3 study in Insomia DisorderIdorsia Pharmaceuticals · NCT07843329 · 344 planned · United States

Ahead

  1. Nov 22, 2027Primary completion: phase 3 study in Insomia DisorderIdorsia Pharmaceuticals · NCT07843329

TargetBeta

“Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist”ChEMBL 37, by rule

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07843329Insomia Disorder · United States3RecruitingIdorsia PharmaceuticalsNov 22, 2027344
NCT07028697Sleep Initiation and Maintenance Disorders · South Korea3CompletedNxera Pharma KoreaSep 23, 2025164
NCT06326723Healthy Volunteer · China1CompletedSimcere Pharmaceutical GroupDec 24, 202332
NCT06010693Sleep Initiation and Maintenance Disorders · China3CompletedSimcere Pharmaceutical GroupApr 12, 2024206
NCT05877222Healthy · United States1CompletedIdorsia PharmaceuticalsAug 4, 202338
NCT05702177Healthy · Netherlands1CompletedIdorsia PharmaceuticalsApr 25, 202336
NCT05632393Healthy · United States1CompletedIdorsia PharmaceuticalsApr 30, 202310
NCT05597020Sleep Initiation and Maintenance Disorders · United States, Germany, Spain4CompletedIdorsia PharmaceuticalsApr 12, 202460
NCT05480488Healthy · Germany1CompletedIdorsia PharmaceuticalsSep 23, 202218
NCT05480475Healthy · Czechia1CompletedIdorsia PharmaceuticalsSep 17, 202224
NCT05458193Obstructive Sleep Apnea of Adult · Germany1CompletedIdorsia PharmaceuticalsFeb 28, 202320
NCT05423717Sleep Initiation and Maintenance Disorders · United States, Bulgaria, Germany and more2CompletedIdorsia PharmaceuticalsJan 12, 2026166
NCT04390334Healthy · Germany1CompletedIdorsia PharmaceuticalsJun 26, 202024
NCT04250506Healthy · Czechia1CompletedIdorsia PharmaceuticalsJul 22, 202036
NCT04024332Renal Insufficiency · Germany1CompletedIdorsia PharmaceuticalsAug 14, 202016
NCT03907215Healthy · Germany1CompletedIdorsia PharmaceuticalsJun 26, 201924
NCT03892902Healthy · Netherlands1CompletedIdorsia PharmaceuticalsOct 10, 201956
NCT03799978Healthy · Czechia1CompletedIdorsia PharmaceuticalsMar 18, 201920
NCT03765294Sleep Apnea, Obstructive · Germany1CompletedIdorsia PharmaceuticalsNov 5, 201928
NCT03713242Hepatic Impairment · Switzerland1CompletedIdorsia PharmaceuticalsFeb 27, 202032
NCT03679884Sleep Initiation and Maintenance Disorders · United States, Belgium, Bulgaria and more3CompletedIdorsia PharmaceuticalsFeb 22, 2021804
NCT03657355Healthy Recreational Drug Users · United States, Canada1CompletedIdorsia PharmaceuticalsAug 8, 201963
NCT03646864Pulmonary Disease, Chronic Obstructive · Germany1CompletedIdorsia PharmaceuticalsSep 19, 201928
NCT03609775Healthy · Netherlands1CompletedIdorsia PharmaceuticalsOct 9, 201822
NCT03545191Sleep Initiation and Maintenance Disorders · United States, Australia, Canada and more3CompletedIdorsia PharmaceuticalsJan 25, 2020930
NCT03575104Sleep Initiation and Maintenance Disorders · United States, Belgium, Bulgaria and more3CompletedIdorsia PharmaceuticalsApr 9, 2020924
NCT03339752Healthy Subjects · Czechia1CompletedIdorsia PharmaceuticalsDec 2, 201720
NCT03101189Healthy Subjects · Netherlands1CompletedIdorsia PharmaceuticalsApr 24, 201740
NCT03017495Healthy Subjects · Germany1CompletedIdorsia PharmaceuticalsFeb 1, 201720
NCT02919319Healthy Subjects · Netherlands1CompletedIdorsia PharmaceuticalsMay 1, 201540
NCT02841709Sleep Initiation and Maintenance Disorders · United States, Germany2CompletedIdorsia PharmaceuticalsMay 31, 201758
NCT02839200Sleep Initiation and Maintenance Disorders · United States, Germany, Hungary and more2CompletedIdorsia PharmaceuticalsApr 12, 2017360
NCT02571855Sleep Initiation and Maintenance Disorders · Netherlands1CompletedIdorsia PharmaceuticalsFeb 1, 201685
NCT02526888Healthy Subjects · Germany1CompletedIdorsia PharmaceuticalsNov 1, 201514

How it is read

Names in the registry

  • “Daridorexant”, 12 entries
  • “ACT-541468”, 12 entries
  • “Daridorexant 25 mg”, 5 entries
  • “Daridorexant 50 mg”, 4 entries
  • “Daridorexant 10 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.